Related Experiment Videos
Does chemotherapy for head and neck cancer improve symptoms?
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2023
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology·2019
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2018
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
Annals of oncology : official journal of the European Society for Medical Oncology·2018
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2016
Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.
Clinical and translational science·2016
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States.
Human vaccines & immunotherapeutics·2026
CD7 CAR-T cells eliminate chronic myeloid leukemia stem cells specifically and effectively.
Hematology (Amsterdam, Netherlands)·2026
Impact of Immunotherapy Prescribing Restrictions on Time to Systemic Therapy and Outcomes in Metastatic Clear Cell Renal Carcinoma in Australia.
Asia-Pacific journal of clinical oncology·2026